The hallmark of the Lung Cancer Study Group (LCSG) was its multidisciplinary approach to cancer management, based on close collaboration among thoracic surgeons, medical oncologists, radiation oncologists, pathologists, biostatisticians, and data managers. Discontinuation of funding for the group dispersed a critical mass of thoracic oncologists and had serious adverse effects on clinical trials in early-stage thoracic malignancies, on translational research, and on oncologic education. The use of an intergroup mechanism for clinical trials has been partially successful in continuing the work started by the LCSG, but a sustained effort will be necessary to recreate the framework for clinical investigation provided by the group. The LCSG was criticized for taking 5 to 7 years to complete some of its phase 3 randomized trials, and it was assumed that the larger cooperative groups would be able to complete such trials more quickly because of access to a larger pool of patients. It was also assumed that those groups would automatically have in place knowledgeable and enthusiastic thoracic surgical oncologists, and that the close collaboration among oncologic specialties present in the LCSG would quickly be duplicated. However, many of the medical and radiation oncologists had no experience working with each other or with surgical oncologists in this manner.
The hallmark of the Lung Cancer Study Group (LCSG) was its multidisciplinary approach to cancer management, based on close collaboration among thoracic surgeons, medical oncologists, radiation oncologists, pathologists, biostatisticians, and data managers. Discontinuation of funding for the group dispersed a critical mass of thoracic oncologists and had serious adverse effects on clinical trials in early-stage thoracic malignancies, on translational research, and on oncologic education. The use of an intergroup mechanism for clinical trials has been partially successful in continuing the work started by the LCSG, but a sustained effort will be necessary to recreate the framework for clinical investigation provided by the group. The LCSG was criticized for taking 5 to 7 years to complete some of its phase 3 randomized trials, and it was assumed that the larger cooperative groups would be able to complete such trials more quickly because of access to a larger pool of patients. It was also assumed that those groups would automatically have in place knowledgeable and enthusiastic thoracic surgical oncologists, and that the close collaboration among oncologic specialties present in the LCSG would quickly be duplicated. However, many of the medical and radiation oncologists had no experience working with each other or with surgical oncologists in this manner. The mutual fund of knowledge and the interchange necessary for successful multidisciplinary trials were absent. Since the dissolution of the LCSG in 1989, none of the other cooperative groups has individually been able to complete a phase 3 randomized trial because they simply did not have in place the proper framework to do so. Adequate accrual to such trials is only beginning to occur through the intergroup mechanism that has brought back together some of the critical mass of thoracic oncologists dispersed by dissolution of the LCSG.1 2 The discontinuation of funding for the LCSG had serious ramifications in two other areas. Because the group was small, had a flexible administrative structure, and free interchange among specialties, it allowed young thoracic oncologists to learn about clinical trials, to present new scientific ideas, and to participate in the group. This was particularly important for thoracic surgeons who are often intimidated into not participating in other groups because of their personal inexperience in clinical trials methodology, the dearth of surgical leadership, and the cumbersome administrative structure in the larger cooperative groups. Rather than fostering surgical participation by a larger number of thoracic surgeons, the dissolution of the LCSG has made it harder to organize and encourage such participation. Indeed, virtually all thoracic surgeons actively participating in cooperative group trials today were either participants in the LCSG or were trained by members of the LCSG.3,4
The final consequence of the dissolution of the LCSG was the interruption of a burgeoning effort in translational research. The LCSG recognized that combining standard treatment modalities in adjuvant or neoadjuvant trials led to only modest changes in clinical outcome, and that significant improvements in therapy would depend on understanding the fundamental biology of cancer. The group also understood that it was uniquely positioned to perform translational research because of its ability to correlate pathologic and molecular biologic alterations with the stage and clinical course of disease. In the latter half of its existence, the LCSG made a conscious decision to pursue collaborative research efforts with several basic scientists. As illustrated by the reports provided in this supplement, these collaborative efforts were remarkably successful in a very short period of time. Unfortunately, this was an idea slightly ahead of its time. The importance of translational research by cooperative groups was not generally recognized, and the LCSG was severely criticized at its site visits for pursuing "nontherapeutic ancillary trials." Now, each of the larger cooperative groups is struggling unsuccessfully to recreate the scientific efforts established by the LCSG. Straightforward correlations of molecular biologic abnormalities with clinical findings that were planned by the LCSG and that could have been accomplished easily within another 2 to 3 years were never done because of discontinued funding. At gical data forms is pivotal in such trials and is relatively labor-intensive. Funding for this portion of clinical trials must be allocated either through separate grant mechanisms for surgeons, through capitation funding for patient accrual, or through inclusion of surgeons and their data managers on the institutional grants submitted at each cooperative group site visit. Surgeons also need funding to travel to cooperative group meetings so that they can participate in scientific and administrative activities on a par with medical and radiation oncologists.
Nonparticipating surgeons will participate in clinical trials only if they have the knowledge, the incentive, and the ability to do so. Many lack knowledge about clinical trials methodology, about the cooperative groups, and how they function. It is incumbent upon surgeons experienced in these areas to share that knowledge through postgraduate courses at thoracic surgical meetings, through publications, including summaries of active cooperative group trials3 and surgical handbooks that codify guidelines for staging and resection in clinical trials.5 Most importantly, residents and fellows must be educated, or future generations of surgeons will also fail to contribute to clinical trials. Specific didactic courses in biostatistics and clinical trials methodology should be a required part of thoracic surgical training. Residents and fellows should be taken to cooperative group meetings by mentors in their training program so they can learn how the groups function and how oncologists from various specialties interact. Individuals planning to focus on general thoracic surgery must be taught that participation in clinical trials is an important and integral part of their practice just as it is for the vast majority of medical and radiation oncologists.
The education of oncologists unused to performing clinical trials in early-stage cancers will be difficult. It There is no current mechanism or forum that can really replace the LCSG. The discontinuation of funding for the group had serious adverse consequences for clinical trials, translational research, and oncologic education. In fact, the LCSG does need to be reestablished, but it is unlikely that funding for such a group will ever be made available again. Hopefully, it will be possible to redevelop an effective framework for clinical trials in early-stage thoracic cancers and to expand this framework to a larger number of academic and community institutions, but a sustained effort at several levels will be required to achieve this.
